Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression.
Shin
D M
DM
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Mao
L
L
Papadimitrakopoulou
V M
VM
Clayman
G
G
El-Naggar
A
A
Shin
H J
HJ
Lee
J J
JJ
Lee
J S
JS
Gillenwater
A
A
Myers
J
J
Lippman
S M
SM
Hittelman
W N
WN
Hong
W K
WK
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000008:administration & dosage; D015474:Isotretinoin / Q000008:administration & dosage; D009154:Mutation / Q000187:drug effects*; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011446:Prospective Studies; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D014810:Vitamin E / Q000008:administration & dosage
D016588:Anticarcinogenic Agents; D016898:Interferon-alpha; D016159:Tumor Suppressor Protein p53; D014810:Vitamin E; D015474:Isotretinoin